Key Highlights
- $50 million raised in Series C equity round and debt facility, led by Soleus Capital, with notable investors like Janus Henderson and Marshall Wace.
- Funds aimed to fuel expansion and meet growing demand for Parse’s innovative single cell sequencing solutions.
- Broad adoption of Parse’s technology in pharmaceutical and academic research, expanding to international markets including Europe and Asia.
Source: Business Wire
Notable Quotes
- “Customer response to our products has been extraordinary… The resounding support from investors will further our mission to make scalable single cell projects routine.” – Alex Rosenberg, Ph.D., CEO and Co-founder at Parse Biosciences
- “Parse’s unique technology is enabling investigators to conduct groundbreaking research and expand the overall genomics market.” – David Canner, Partner at Soleus Capital
- “We are excited to support Parse as it develops new genomic solutions and further expands its operations.” – Gerald A. Michaud, President at Horizon
SoH's Take
Parse Biosciences’ significant funding round marks a pivotal moment in the field of genomics and single cell sequencing. The substantial investment underscores the industry’s recognition of the potential impact of Parse’s technology in advancing human health research. With this financial backing, Parse is well-positioned to escalate its market presence, further develop its pioneering technology, and address the escalating demands of the scientific community. The expansion of their technology to new international markets signifies the global relevance and potential of their innovations. This move not only solidifies their standing in the genomics sector but also promises substantial contributions to the future of healthcare and medical research.
